MUC16 and ovarian carcinoma: One of the most notable diagnostic biomarkers is MUC16 (Ferrer, 2023), which is widely used in ovarian cancer assessment, however, it has limited use as an independent endpoint for drug treatment selection (Herzog et al., 2017).